1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Dietary ω-3 fatty acids protect against vasculopathy in a transgenic mouse model of sickle cell disease.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The anemia of sickle cell disease is associated with a severe inflammatory vasculopathy and endothelial dysfunction, which leads to painful and life-threatening clinical complications. Growing evidence supports the anti-inflammatory properties of ω-3 fatty acids in clinical models of endothelial dysfunction. Promising but limited studies show potential therapeutic effects of ω-3 fatty acid supplementation in sickle cell disease. Here, we treated humanized healthy and sickle cell mice for 6 weeks with ω-3 fatty acid diet (fish-oil diet). We found that a ω-3 fatty acid diet: (i) normalizes red cell membrane ω-6/ω-3 ratio; (ii) reduces neutrophil count; (iii) decreases endothelial activation by targeting endothelin-1 and (iv) improves left ventricular outflow tract dimensions. In a hypoxia-reoxygenation model of acute vaso-occlusive crisis, a ω-3 fatty acid diet reduced systemic and local inflammation and protected against sickle cell-related end-organ injury. Using isolated aortas from sickle cell mice exposed to hypoxia-reoxygenation, we demonstrated a direct impact of a ω-3 fatty acid diet on vascular activation, inflammation, and anti-oxidant systems. Our data provide the rationale for ω-3 dietary supplementation as a therapeutic intervention to reduce vascular dysfunction in sickle cell disease.

          Related collections

          Author and article information

          Journal
          Haematologica
          Haematologica
          Ferrata Storti Foundation (Haematologica)
          1592-8721
          0390-6078
          Jul 2015
          : 100
          : 7
          Affiliations
          [1 ] Department of Surgery and The Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
          [2 ] Department of Medicine, University of Verona-AOUI Verona, Policlinico GB Rossi, Verona, Italy.
          [3 ] Department of Biochemistry, University Federico II, Naples, Italy.
          [4 ] Departments of Pathology and Laboratory Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
          [5 ] Molecular Biotechnology Center and Department of Molecular Biotechology and Health Science, University of Turin, Italy.
          [6 ] Departments of Pathology and Laboratory Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA carlo.brugnara@childrens.harvard.edu.
          Article
          haematol.2015.124586
          10.3324/haematol.2015.124586
          4486221
          25934765
          083b32a6-c84f-4fad-9a3b-dc6e6b02e87c
          History

          Comments

          Comment on this article